Multiple Sclerosis Functional Composite (MSFC): Difference between revisions
Memoona Awan (talk | contribs) (reference) |
Memoona Awan (talk | contribs) (reference purpose and technique) |
||
| Line 5: | Line 5: | ||
==Purpose == | ==Purpose == | ||
The Multiple Sclerosis Functional Composite (MSFC) designed by "National MS Society's Clinical Outcome Assessment Task" and is a standardized tool used to quantify degree of disability in patients with multiple sclerosis (MS)<ref>JS, RA, GR, SC. F Rudick, Cutter, Reingold. [https://journals.sagepub.com/doi/10.1177/135245859900500409?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200pubmed The Multiple Sclerosis Functional Composite measure (MSFC): an integrated approach to MS clinical outcome assessment.] Multiple Sclerosis Journal [Internet]. 1999 [cited 2024 Mar 1];5(4):244–250.</ref>. Limitations in EDSS leads to development of MSFC in the early 1990's, to improve clinical assessment of patients with multiple sclerosis<ref>Cutter GR, Baier ML, Rudick RA, Cookfair DL, Fischer JS, Petkau J, . [https://academic.oup.com/brain/article/122/5/871/296648 Development of a multiple sclerosis functional composite as a clinical trial outcome measure]. Brain [Internet]. 1999 [cited 2024 Mar 1];122(5):871–882. </ref><ref>Van Munster, C. E., & Uitdehaag, B. M. [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5336539/#CR40 Outcome Measures in Clinical Trials for Multiple Sclerosis.] CNS drugs. 2017;31(3):217–236.</ref>. | The Multiple Sclerosis Functional Composite (MSFC) designed by "National MS Society's Clinical Outcome Assessment Task" and is a standardized tool used to quantify degree of disability in patients with multiple sclerosis (MS)<ref name=":0">JS, RA, GR, SC. F Rudick, Cutter, Reingold. [https://journals.sagepub.com/doi/10.1177/135245859900500409?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200pubmed The Multiple Sclerosis Functional Composite measure (MSFC): an integrated approach to MS clinical outcome assessment.] Multiple Sclerosis Journal [Internet]. 1999 [cited 2024 Mar 1];5(4):244–250.</ref>. Limitations in EDSS leads to development of MSFC in the early 1990's, to improve clinical assessment of patients with multiple sclerosis<ref>Cutter GR, Baier ML, Rudick RA, Cookfair DL, Fischer JS, Petkau J, . [https://academic.oup.com/brain/article/122/5/871/296648 Development of a multiple sclerosis functional composite as a clinical trial outcome measure]. Brain [Internet]. 1999 [cited 2024 Mar 1];122(5):871–882. </ref><ref name=":1">Van Munster, C. E., & Uitdehaag, B. M. [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5336539/#CR40 Outcome Measures in Clinical Trials for Multiple Sclerosis.] CNS drugs. 2017;31(3):217–236.</ref>. The traditional scales such as EDSS scale are inadequate in measuring some key aspects of MS for example cognitive function and have psychometric limitations as well<ref name=":0" />. | ||
==Technique == | ==Technique == | ||
MSFC covers three functional domains<ref name=":1" />: | |||
# Ambulatory Function | |||
# Hand Function | |||
# Cognitive function | |||
The results of the tests that assess these domains are depicted in an interval scale (seconds or number of correct responses) and can be converted to a ''Z'' score that is based on values of a reference population [<nowiki/>[[/www.ncbi.nlm.nih.gov/pmc/articles/PMC5336539/#CR42|42]]]. An overall score can be calculated by averaging the ''Z'' score of the subtests. | |||
==Evidence== | ==Evidence== | ||
| Line 14: | Line 24: | ||
==Resources== | ==Resources== | ||
[https://www.nationalmssociety.org/nationalmssociety/media/msnationalfiles/brochures/10-2-3-31-msfc_manual_and_forms.pdf#:~:text=This%20manual%20provides%20general%20instructions%20about%20the,their%20knowledge%20of%20key%20aspects%20of%20MSFC Guidebook] | [https://www.nationalmssociety.org/nationalmssociety/media/msnationalfiles/brochures/10-2-3-31-msfc_manual_and_forms.pdf#:~:text=This%20manual%20provides%20general%20instructions%20about%20the,their%20knowledge%20of%20key%20aspects%20of%20MSFC Guidebook] | ||
[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6278631/ Scoring guideline] | |||
==References== | ==References== | ||
Revision as of 18:35, 2 March 2024
This article or area is currently under construction and may only be partially complete. Please come back soon to see the finished work! (2/03/2024)
Purpose[edit | edit source]
The Multiple Sclerosis Functional Composite (MSFC) designed by "National MS Society's Clinical Outcome Assessment Task" and is a standardized tool used to quantify degree of disability in patients with multiple sclerosis (MS)[1]. Limitations in EDSS leads to development of MSFC in the early 1990's, to improve clinical assessment of patients with multiple sclerosis[2][3]. The traditional scales such as EDSS scale are inadequate in measuring some key aspects of MS for example cognitive function and have psychometric limitations as well[1].
Technique[edit | edit source]
MSFC covers three functional domains[3]:
- Ambulatory Function
- Hand Function
- Cognitive function
The results of the tests that assess these domains are depicted in an interval scale (seconds or number of correct responses) and can be converted to a Z score that is based on values of a reference population [42]. An overall score can be calculated by averaging the Z score of the subtests.
Evidence[edit | edit source]
Provide the evidence for this technique here
Resources[edit | edit source]
References[edit | edit source]
- ↑ 1.0 1.1 JS, RA, GR, SC. F Rudick, Cutter, Reingold. The Multiple Sclerosis Functional Composite measure (MSFC): an integrated approach to MS clinical outcome assessment. Multiple Sclerosis Journal [Internet]. 1999 [cited 2024 Mar 1];5(4):244–250.
- ↑ Cutter GR, Baier ML, Rudick RA, Cookfair DL, Fischer JS, Petkau J, . Development of a multiple sclerosis functional composite as a clinical trial outcome measure. Brain [Internet]. 1999 [cited 2024 Mar 1];122(5):871–882.
- ↑ 3.0 3.1 Van Munster, C. E., & Uitdehaag, B. M. Outcome Measures in Clinical Trials for Multiple Sclerosis. CNS drugs. 2017;31(3):217–236.
